Compare TARA & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARA | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.9M | 238.1M |
| IPO Year | 2014 | 2017 |
| Metric | TARA | PROF |
|---|---|---|
| Price | $5.47 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $24.40 | $12.00 |
| AVG Volume (30 Days) | ★ 572.7K | 83.7K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | $2,948,000.00 | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $4.79 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.77 | $3.92 |
| 52 Week High | $7.82 | $8.95 |
| Indicator | TARA | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 58.75 |
| Support Level | $4.92 | $7.00 |
| Resistance Level | $5.47 | $7.97 |
| Average True Range (ATR) | 0.26 | 0.41 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 72.46 | 90.72 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.